Thursday Dec 12, 2024
Thursday Dec 12, 2024
Wednesday, 2 December 2015 00:00 - - {{hitsCtrl.values.hits}}
The GSK team with the four awards won at the 2015 National Business Excellence Awards
GlaxoSmithKline’s (GSK’s) Sri Lanka operations, encompassing pharmaceuticals and consumer nutritionals, won four National Business Excellence Awards (NBEAs) at the 2015 edition of the apex awards event of the National Chamber of Commerce, including the overall runner-up award across all categories and sectors.
Equalling its performance of last year, GSK won the Gold for ‘Performance Management’ in the Criteria Awards, the Gold for ‘Healthcare Related Services’ in the Sector Awards, the Silver in the ‘Extra Large Category’ in the Category Awards across all sectors, in addition to its Silver in the ‘Overall Winners’ group.
A total of 92 awards were presented to 62 shortlisted companies in 29 sectors of business at this year’s National Business Excellence Awards, presented for the 12th consecutive year. For GSK, 2015 was its second year of participation in the awards program.
“Being adjudged the second overall for business excellence among companies in diverse areas of business is an excellent affirmation of the balanced, socially-responsible performance model of GSK,” Stuart Chapman, Managing Director of GSK Pharmaceuticals in Sri Lanka said. “The multi-dimensional evaluation for these awards emphasises that business is not just about doing well, it is also about doing it right. We are therefore greatly encouraged by the endorsement of the eminent panel of judges for these awards.”
Winners of National Business Excellence Awards are assessed to a marking scheme that encompasses Excellence in Leadership, Excellence in Corporate Governance, Excellence in Capacity Building, Excellence in Performance Management, Excellence in Local and Global Market Reach, Excellence in Corporate Social Responsibility and Environmental Sustainability and Excellence in Business and Financial Results. All applicant companies are interviewed by the judges to validate the information provided.
In January this year, GSK Pharmaceuticals adopted a trailblazing new sales force remuneration programme in Sri Lanka, eliminating individual sales targets. The new remuneration methodology is based on the core principle that GSK Pharmaceuticals will not link remuneration to individual sales representatives with the achievement of sales targets. Instead, the company’s sales representatives are now evaluated and rewarded for their technical skills, scientific knowledge and customer understanding, the quality of the service they deliver to support improved patient care and the overall performance of GSK’s business.
This industry-leading initiative is aligned with GSK’s values and puts patients’ interest at the centre of all company decisions.
One of the world’s leading research-based pharmaceutical, consumer health and vaccines companies, GSK is committed to improving the quality of human life by enabling people to do more, feel better and live longer. GSK and its predecessors have been doing business in Sri Lanka since the late 1930s. GSK is the first and only multinational company to manufacture pharmaceuticals in Sri Lanka.
